{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:43:43Z","timestamp":1790700223433,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2020.00372","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T10:56:00Z","timestamp":1595588160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["CFTR Modulators Dampen Aspergillus-Induced Reactive Oxygen Species Production by Cystic Fibrosis Phagocytes"],"prefix":"10.3389","volume":"10","author":[{"given":"Alexander J.","family":"Currie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen T.","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Armstrong-James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adilia","family":"Warris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1074\/jbc.M112.411728","article-title":"Depletion of the ubiquitin-binding adaptor molecule SQSTM1\/p62 from macrophages harboring CFTR \u0394F508 mutation improves the delivery of Burkholderia cenocepacia to the autophagic machinery","volume":"288","author":"Abdulrahman","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/21678707.2020.1713748","article-title":"Gram negative infections in cystic fibrosis: a review of preventative and treatment options","volume":"8","author":"Addy","year":"2020","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1183\/13993003.01475-2015","article-title":"A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma","volume":"47","author":"Agarwal","year":"2016","journal-title":"Eur. Respir. J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1378\/chest.09-1103","article-title":"The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis","volume":"137","author":"Amin","year":"2010","journal-title":"Chest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"L432","DOI":"10.1152\/ajplung.00461.2017","article-title":"Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa","volume":"314","author":"Barnaby","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.smim.2017.08.007","article-title":"Recent advances in clinical development of leukotriene B4 pathway drugs","volume":"33","author":"Bhatt","year":"2017","journal-title":"Semin. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1128\/AAC.49.6.2372-2377.2005","article-title":"Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin","volume":"49","author":"Bosnar","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1164\/rccm.201810-1919OC","article-title":"Changing prevalence of lower airway infections in young children with cystic fibrosis","volume":"200","author":"Breuer","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"00068","DOI":"10.1183\/23120541.00068-2017","article-title":"Aspergillus-induced superoxide production by cystic fibrosis phagocytes is associated with disease severity","volume":"4","author":"Brunel","year":"2018","journal-title":"ERJ Open Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/ijms18122666","article-title":"Azithromycin and chloramphenicol diminish neutrophil extracellular traps (NETs) release","volume":"18","author":"Bystrzycka","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jcf.2005.12.003","article-title":"Dysregulated interleukin-8 secretion and NF-\u03baB activity in human cystic fibrosis nasal epithelial cells","volume":"5","author":"Carrabino","year":"2006","journal-title":"J. Cyst. Fibros."},{"key":"B12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.bbrc.2006.09.132","article-title":"Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells","volume":"350","author":"Cigana","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/MCP.0b013e32835f1afc","article-title":"Respiratory bacterial infections in cystic fibrosis","volume":"19","author":"Ciofu","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jcf.2015.02.006","article-title":"Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin","volume":"14","author":"Coolen","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e46450","DOI":"10.7554\/eLife.46450","article-title":"Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations","volume":"8","author":"Csan\u00e1dy","year":"2019","journal-title":"eLife"},{"key":"B16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Culi\u0107","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e19970","DOI":"10.1371\/journal.pone.0019970","article-title":"Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa","volume":"6","author":"Del Porto","year":"2011","journal-title":"PLoS ONE"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35926","DOI":"10.1074\/jbc.M109.057372","article-title":"Disease-causing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages","volume":"284","author":"Deriy","year":"2009","journal-title":"J. Biol. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: current and future strategies","volume":"11","author":"D\u00f6ring","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cct.2018.07.014","article-title":"EMPIRE-CF: a phase II randomized placebo-controlled trial of once-daily, oral acebilustat in adult patients with cystic fibrosis\u2013study design and patient demographics","volume":"72","author":"Elborn","year":"2018","journal-title":"Contemp. Clin. Trials"},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cts.12426","article-title":"Phase I studies of acebilustat: pharmacokinetics, pharmacodynamics, food effect, and CYP3A induction","volume":"10","author":"Elborn","year":"","journal-title":"Clin. Transl. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/cts.12428","article-title":"Phase I studies of acebilustat: biomarker response and safety in patients with cystic fibrosis","volume":"10","author":"Elborn","year":"","journal-title":"Clin. Transl. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1513\/AnnalsATS.201902-122OC","article-title":"Ivacaftor is associated with reduced lung infection by key cystic fibrosis pathogens. A cohort study using national registry data","volume":"16","author":"Frost","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jcf.2012.07.003","article-title":"Innate immunity in cystic fibrosis lung disease","volume":"11","author":"Hartl","year":"2012","journal-title":"J. Cyst. Fibros."},{"key":"B26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jcf.2019.08.008","article-title":"The presence of Aspergillus fumigatus is associated with worse respiratory quality of life in cystic fibrosis","volume":"19","author":"Hong","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"B28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/ja.2006.80","article-title":"A new antifungal macrolide, eushearilide, isolated from Eupenicillium shearii","volume":"59","author":"Hosoe","year":"2006","journal-title":"J. Antibiot."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e54556","DOI":"10.7554\/eLife.54556","article-title":"Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis","volume":"9","author":"Jarosz-Griffiths","year":"2020","journal-title":"eLife"},{"key":"B30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/cyto.a.22456","article-title":"Detection of CFTR protein in human leukocytes by flow cytometry","volume":"85","author":"Johansson","year":"2014","journal-title":"Cytom. A"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1002\/ppul.23505","article-title":"Therapeutic challenges posed by critical drug\u2013drug interactions in cystic fibrosis","volume":"51","author":"Jordan","year":"2016","journal-title":"Pediatr. Pulmonol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ppul.21240","article-title":"Risk factors for Aspergillus colonization and allergic bronchopulmonary aspergillosis in children with cystic fibrosis","volume":"45","author":"Jubin","year":"2010","journal-title":"Pediatr. Pulmonol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.7164\/antibiotics.56.448","article-title":"Takanawaenes, novel antifungal antibiotics produced by Streptomyces sp. K99-5278","volume":"56","author":"Kim","year":"2003","journal-title":"J. Antibiot."},{"key":"B34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1753465815601934","article-title":"Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects","volume":"9","author":"Kuk","year":"2015","journal-title":"Ther. Adv. Respir. Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1902\/jop.2014.140183","article-title":"Azithromycin enhances phagocytic killing of Aggregatibacter actinomycetemcomitans Y4 by human neutrophils","volume":"86","author":"Lai","year":"2015","journal-title":"J. Periodontol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1465-9921-7-134","article-title":"Azithromycin reduces spontaneous and induced inflammation in \u0394F508 cystic fibrosis mice","volume":"7","author":"Legssyer","year":"2006","journal-title":"Respir. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/ncb2090","article-title":"Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition","volume":"12","author":"Luciani","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4161\/auto.7.1.13987","article-title":"Cystic fibrosis: a disorder with defective autophagy","volume":"7","author":"Luciani","year":"2011","journal-title":"Autophagy"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.4161\/auto.21483","article-title":"Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on \u0394F508 cystic fibrosis transmembrane conductance regulator","volume":"8","author":"Luciani","year":"2012","journal-title":"Autophagy"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/17476348.2019.1666715","article-title":"Targeting airway inflammation in cystic fibrosis","volume":"13","author":"McElvaney","year":"2019","journal-title":"Expert Rev. Respir. Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1046\/j.1365-2249.2000.01232.x","article-title":"Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes","volume":"120","author":"Moss","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1165\/rcmb.2010-0224OC","article-title":"Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses","volume":"44","author":"Mueller","year":"2011","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1002\/ppul.23242","article-title":"Inflammation and its genesis in cystic fibrosis","volume":"50","author":"Nichols","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.1021\/bi060490t","article-title":"CFTR expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis","volume":"45","author":"Painter","year":"2006","journal-title":"Biochemistry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejphar.2005.05.023","article-title":"Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment","volume":"517","author":"Parnham","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ijantimicag.2017.04.014","article-title":"Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens","volume":"50","author":"Payne","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B48","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1182\/blood-2014-02-555268","article-title":"A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy","volume":"124","author":"Pohl","year":"2014","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10096-015-2347-4","article-title":"Azithromycin use in patients with cystic fibrosis","volume":"34","author":"Principi","year":"2015","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jcf.2014.02.004","article-title":"Antibacterial properties of the CFTR potentiator ivacaftor","volume":"13","author":"Reznikov","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1152\/jappl.1993.75.6.2419","article-title":"Systemic deficiency of glutathione in cystic fibrosis","volume":"75","author":"Roum","year":"1993","journal-title":"J. Appl. Physiol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"L635","DOI":"10.1152\/ajplung.00198.2017","article-title":"Vx-809\/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells","volume":"314","author":"Ruffin","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1021\/acsinfecdis.6b00035","article-title":"An \u201cunlikely\u201d pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI","volume":"2","author":"Schneider","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1093\/mmy\/myy074","article-title":"Aspergillus colonization and antifungal immunity in cystic fibrosis patients","volume":"57","author":"Warris","year":"2019","journal-title":"Med. Mycol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.4049\/jimmunol.170.12.6273","article-title":"Transepithelial migration of neutrophils in response to leukotriene B4 is mediated by a reactive oxygen species-extracellular signal-regulated kinase-linked cascade","volume":"170","author":"Woo","year":"2003","journal-title":"J. Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000346568","article-title":"Cystic fibrosis transmembrane conductance regulator recruitment to phagosomes in neutrophils","volume":"5","author":"Zhou","year":"2013","journal-title":"J. Innate Immun."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00372\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T10:56:04Z","timestamp":1595588164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00372\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":57,"alternative-id":["10.3389\/fcimb.2020.00372"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2020.00372","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"article-number":"372"}}